Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy TranscriptSeeking Alpha · 14 hr ago
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 TrialMarketBeat · 15 hr ago
Breakfast News: A Conversation With Moderna's CEOThe Motley Fool · 1 day ago
Heard on the Street: Moderna's cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.WSJ · 1 day ago
To the scientific world, Moderna's cancer vaccine's results proved that a highly personalized, immune-targeting medication can work. To investors, it didn't work well enough.WSJ · 1 day ago
The real test for Moderna's cancer vaccine isn't about beating Keytruda. It's keeping cancer from coming back in the long term.Market Watch · 1 day agoModerna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 31, 2026 | -$2.03 | -$1.97 | Beat |
| May 1, 2026 | -$4.45 | -$3.40 | Beat |
| Feb 13, 2026 | -$2.54 | -$2.11 | Beat |
| Nov 6, 2025 | -$1.87 | -$0.51 | Beat |
| Aug 1, 2025 | -$2.99 | -$2.13 | Beat |
| May 1, 2025 | -$2.92 | -$2.52 | Beat |